KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $485,787 | -43.3% | 15,238 | -28.5% | 0.00% | – |
| Q2 2023 | $856,758 | +40.2% | 21,323 | +49.0% | 0.00% | – |
| Q1 2023 | $610,909 | +26967.3% | 14,307 | +30340.4% | 0.00% | – |
| Q4 2022 | $2,257 | -91.0% | 47 | -92.9% | 0.00% | – |
| Q3 2022 | $25,000 | -78.3% | 665 | -84.1% | 0.00% | – |
| Q2 2022 | $115,000 | +42.0% | 4,177 | +181.7% | 0.00% | – |
| Q1 2022 | $81,000 | -79.8% | 1,483 | -78.3% | 0.00% | – |
| Q4 2021 | $400,000 | – | 6,834 | +227700.0% | 0.00% | – |
| Q3 2021 | $0 | – | 3 | -66.7% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 9 | -97.9% | 0.00% | – |
| Q1 2021 | $27,000 | -98.0% | 431 | -97.8% | 0.00% | – |
| Q4 2020 | $1,376,000 | +184.9% | 19,514 | +55.8% | 0.00% | – |
| Q3 2020 | $483,000 | +7.1% | 12,522 | +4.2% | 0.00% | – |
| Q2 2020 | $451,000 | – | 12,023 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |